TacticScaleWhat Vir Biotechnology Does & How It Makes Money (VIR)
Updated October 2026 · reflects Vir Biotechnology's latest reported financials
Clinical-stage biotech developing treatments for infectious diseases and cancer. As a clinical-stage company, Vir has no approved products to sell in this pipeline.
How Vir Biotechnology makes money
As a clinical-stage company, Vir has no approved products to sell in this pipeline. Its income comes from collaboration, license and grant agreements with partners such as Astellas, Norgine, Alnylam, GSK and the Gates Foundation, and it hopes to earn product revenue if its candidates are approved.
What Vir Biotechnology does
Vir Biotechnology is a San Francisco-based clinical-stage biopharmaceutical company founded in 2016. It develops medicines to treat and prevent serious infectious diseases. Its clinical pipeline centers on therapies for hepatitis delta virus (HDV) and solid tumors. Earlier-stage candidates include influenza A and B antibodies and antibody drug conjugates, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T-cell engagers for a range of solid tumors. Vir relies heavily on partnerships. It has licensing and collaboration agreements with Astellas, Norgine, Brii Biosciences, Alnylam, Xencor, the Institute for Research in Biomedicine and The Rockefeller University. It also has a research collaboration with GSK and a funding agreement with the Gates Foundation. Because it is still in the clinical stage, its value depends on trial results and whether regulators approve its drugs.
Products & services
- Hepatitis delta virus (HDV) investigational therapies
- PRO-XTEN dual-masked T-cell engagers (TCEs) for solid tumors
- Influenza A and B antibodies and antibody drug conjugates
- Coronavirus monoclonal antibodies
What is Vir Biotechnology worth?
On an owner-earnings DCF, Vir Biotechnology's most-likely value is about $7 versus a recent price near $12 (40% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Novavax (NVAX) · Gilead Sciences (GILD) · Viatris (VTRS) · TG Therapeutics (TGTX) · Roivant Sciences (ROIV)